Analyzing the efficacy of sofosbuvir in HCV patients infected with 3a genotype in Pakistan
Loading...
Date
2017
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of Management and Technology Lahore
Abstract
Hepatitis C is caused by hepatitis C virus and has infected 11 million people in Pakistan. 97 % of the patients are infected with 3a genotype of HCV. So, Sofosbuvir was used against HCV patients infected with 3a genotype. Methodology: This study was conducted at Mayo hospital Lahore. 217 patients of hepatitis C infected with 3a genotype were included in it. All of them were suffering from compensated chronic liver disease. 52 patients did not give follow up for given reasons: 32 patients could not be contacted to give follow up at the end of therapy and 20 patients were non-compliant. 165 patients continued the therapy with proper follow up, out of which 11 patients discontinued the therapy due to adverse events and 154 patients completed the therapy i.e 24 weeks. 150/154 patients showed positive response and 4 patients showed negative results against therapy. All patients were treated with SOF (once daily) plus RBV (trice a daily). Results: Results of this study came out to be: 150/154 (97 %) patients showed positive response against Sofosbuvir plus ribavirin out of which 59 (36 %) were male and 91 (61 %) were female. Conclusion: Sofosbuvir showed good results against HCV patients infected with 3a genotype in Pakistan.
Description
Supervised by:Dr. Khurram Shahzad Munawar
Keywords
Non-compliant, Negative results, MS Thesis